NEW YORK (GenomeWeb) – MDxHealth announced today that its ConfirmMDx prostate cancer test has received a positive coverage policy decision from Horizon Blue Cross Blue Shield (BCBS) of New Jersey.
According to MDxHealth, Horizon BCBS is New Jersey’s largest insurer with more than 3.8 million members. With the latest policy decision, the company has secured coverage for ConfirmMDx with various BCBS affiliates including Independence Blue Cross and Highmark BCBS, as well as private payors such as Cigna and Priority Health. In September 2016, the test received in-network status for the California Medical Assistance Program.
"The positive coverage decision by Horizon BCBS of New Jersey further validates the clinical and economic value of ConfirmMDx for prostate cancer for health plans, patients, and physicians," MDxHealth CEO Jan Groen said in a statement. "We are pleased to see the growing number of healthcare plans providing coverage for our test, further improving patient outcomes and helping to reduce costs to the US healthcare system."
ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns. Early last year, it was included in the US 2016 National Comprehensive Cancer Network Guidelines for prostate cancer screening.